- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
PAPER OF THE WEEK: Variation in Markups for Oncology Services
This week’s selection was one of our most-read articles of 2018.
Welcome to Paper of the Week, which looks back at some of the most important research and commentary of the past 25 years in The American Journal of Managed Care® and why they matter today.
This week’s selection was one of our most-read articles of 2018.
“Variation in Markups on Outpatient Oncology Services in the United States” found that high variation in markups for cancer care services was an impediment to quality care.
This kind of practice led to the rise of the Oncology Care Model and other alternative payment models in cancer care, which are explored each year at our annual conference, Patient-Centered Oncology Care.
For our paper of the week, visit ajmc.com.
And visit our site for our new issue of Evidence-Based Oncology™ that recaps the 2019 PCOC meeting.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
